1458033-17-4

Basic information

• Product Name: (R)-4-benzyl-3-((R)-4-(benzyloxy)-2-methylbutanoyl) oxazolidin-2-one
• Synonyms: (R)-4-benzyl-3-((R)-4-(benzyloxy)-2-methylbutanoyl) oxazolidin-2-one
• CAS NO: 1458033-17-4
• Molecular Weight: 367.445
• Mol File: 1458033-17-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-4-benzyl-3-((R)-4-(benzyloxy)-2-methylbutanoyl) oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-benzyl-3-((R)-4-(benzyloxy)-2-methylbutanoyl) oxazolidin-2-one(1458033-17-4)
• EPA Substance Registry System: (R)-4-benzyl-3-((R)-4-(benzyloxy)-2-methylbutanoyl) oxazolidin-2-one(1458033-17-4)

Safety Data

• Hazardous Substances Data: 1458033-17-4(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 10385-30-5 4-(benzyloxy)butanoic acid 
• 100-39-0 benzyl bromide 
• 4541-14-4 4-benzyloxy-butan-1-ol 
• 389086-15-1 (4R)-4-benzyl-3-(4-benzyloxy-1-oxobutyl)-2-oxazolidinone 
• 74-88-4 methyl iodide 

Downstream Products

• 96154-47-1 (R)-2-methyl-1,4-butanediol 4-benzyl ether 
• 1458033-18-5 (4S,5R)-7-(benzyloxy)-5-methylhept-1-en-4-ol 
• 1458033-19-6 C₁₇H₂₆O₃ 
• 1458033-20-9 (2R,3R,4R)-6-(benzyloxy)-3-(methoxymethoxy)-4-methylhexane-1,2-diol 
• 1458033-21-0 (R)-2-((1R,2R)-4-(benzyloxy)-1-(methoxymethoxy)-2-methylbutyl)oxirane 
• 1458033-22-1 (5R,6R)-5-((R)-4-(benzyloxy)butan-2-yl)-13,13,14,14-tetramethyl-2,4,12-trioxa-13-silapentadec-8-yn-6-ol 
• 1458033-23-2 (5R,6R,Z)-5-((R)-4-(benzyloxy)butan-2-yl)-13,13,14,14-tetramethyl-2,4,12-trioxa-13-silapentadec-8-en-6-ol 
• 91550-14-0 (2R)-4-(Benzyloxy)-2-methyl-1-butanal 

Relevant articles and documents

A Novel Synthesis of Sex Pheromone from the Longicorn Beetle (Psacothea hilaris)

Abstract: An asymmetric synthesis of (8Z,21R)-21-methylpentatriacont-8-ene, the sex pheromoneof the yellow-spotted longicorn beetle Psacotheahilaris, has been achieved using Evan’s induction as the keystep. Based on the asymmetric methylation product of chiral (R)-4-benzyl-1,3-oxazolidin-2-one, the carbon chainof the target molecule was assembled through aC5+C12+C11+C8sequence. (2R)-4-(Benzyloxy)-2-methylbutan-1-ol, which can be obtained fromγ-lactone following Evan’s protocol, was connected to aC12 alkyl group. The chiral methyl group remained thekey moiety (97% ee). After another Wittigreaction and catalytic hydrogenation step, the designed key intermediate(13R)-13-methylheptacosan-1-ol wasobtained. Finally, after oxidation and Wittig reaction, the synthesis of thetarget molecule was completed in 10 linear steps with an ultra-high overallyield of 36.2%.

SYNUCLEINOPATHY THERAPEUTIC MEDICATION

This invention provides a pharmaceutical composition for treating or preventing synucleinopathy comprising a compound represented by formula (I), or a pharmaceutically acceptable salt thereof.